Patients Experiment With Prescription Drugs To Fight Aging
Kaiser Health News - March 05, 2019
Despite the "off-label" use of some drugs, like metformin, to fight the effects of aging, Nir Barzilai, M.D., believes rigorous clinical trials are necessary to prove their efficacy and safety. Dr. Barzilai is the Ingeborg and Ira Leon Rennert Chair in Aging Research and director of the Institute for Aging Research at Einstein and an endocrinologist at Montefiore.
Will You Really Need a Geriatrician When You’re 65?
The Washington Post - December 19, 2018
Nir Barzilai, M.D., advises patients to consider their health conditions, mobility, level of frailty, and other factors—not simply chronological age—when deciding whether they should see a geriatrician. Dr. Barzilai is the Ingeborg and Ira Leon Rennert Chair in Aging Research and director of the Institute for Aging Research at Einstein and an endocrinologist at Montefiore.
Could Drugs Delay the Diseases of Aging?
BBC News - December 21, 2017
A series on aging features research by Dr. Nir Barzilai, and his planned clinical study on the effects of the drug metformin on age-related disease. Dr. Barzilai is the Ingeborg and Ira Leon Rennert Chair in Aging Research and director of the Institute for Aging Research at Einstein.
Could 'longevity pill' help you live longer and healthier?
Today - September 13, 2017
Maria Shriver interviews Nir Barzilai, M.D., about his planned clinical study on metformin, a common diabetes medication that may delay age-related disease. Dr. Barzilai is director of the Institute for Aging Research and holds the Ingeborg and Ira Leon Rennert Chair in Aging Research at Einstein.
The New York Times interviews Nir Barzilai, M.D., on the development of self-driving cars to serve older adults. Dr. Barzilai is the Ingeborg and Ira Leon Rennert Chair of Aging Research and director of the Institute for Aging Research at Einstein.
March 23, 2017
The Washington Post interviews Nir Barzilai, M.D., about Donald Trump’s health, human aging, and questions about the factors affecting longevity and healthspan. Dr. Barzilai is the Ingeborg and Ira Leon Rennert Chair of Aging Research and director of the Institute for Aging Research at Einstein.
January 18, 2017
U.S. News & World Report interviews Ana Maria Cuervo, M.D., Ph.D., and Nir Barzilai, M.D., about their aging research. Drs. Cuervo and Barzilai are co-directors of Einstein’s Institute for Aging Research.
August 9, 2016
The New York Times interviews Dr. Nir Barzilai, M.D., about his upcoming clinical trial to determine if an existing FDA-approved drug can extend health span. Dr. Barzilai and his collaborators at the American Federation for Aging Research will investigate if metformin, a cheap and commonly used medication to treat type 2 diabetes, can delay the onset of several age-related diseases. Dr. Barzilai is the Ingeborg and Ira Leon Rennert Chair of Aging Research and director of the Institute for Aging Research at Einstein.
More coverage on this story
The Washington Post
February 1, 2016
National Geographic highlights the leadership role Nir Barzilai, M.D., is taking in a clinical trial to determine if a common diabetes drug can delay aging. Dr. Barzilai notes that the goal of the Targeting Aging with Metformin (TAME) study is not to find the “fountain of youth,” but to extend the number of healthy, active years humans can enjoy. Dr. Barzilai is the Ingeborg and Ira Leon Rennert Chair of Aging Research and director of the Institute for Aging Research at Einstein.
More coverage on this story
Forbes
Fox News
PIX 11
National Post (Canada)
The Telegraph
Newsweek
December 3, 2015
Science profiles Nir Barzilai, M.D., and the ambitious proposed clinical trial he is leading that would evaluate if metformin can delay aging in humans. The article details his meeting with FDA, which was supportive of the approach, and the key roles his collaborators at the American Federation for Aging Research are playing in the effort. Dr. Barzilai is the Ingeborg and Ira Leon Rennert Chair of Aging Research and director of the Institute for Aging Research at Einstein.
September 17, 2015
Scientific American interviews Nir Barzilai, M.D., about latest research advances for slowing or delaying the aging process in humans. Dr. Barzilai, who conducts longevity research with centenarians, notes his “superagers” tend to have a significant delay in the onset of age-related diseases and stay healthier longer. Dr. Barzilai is the Ingeborg and Ira Leon Rennert Chair of Aging Research and director of the Institute for Aging Research at Einstein and attending physician at Montefiore Medical Center.
July 1, 2015
Nature features Nir Barzilai, M.D., and his proposed TAME study, which will investigate if the widely used diabetes drug metformin can delay aging. Dr. Barzilai notes that he and his colleagues are not seeking the “fountain of youth,” but rather an effective means to extend the number of healthy years an individual has, or “healthspan.” Dr. Barzilai is the Ingeborg and Ira Leon Rennert Chair of Aging Research and director of the Institute for Aging Research at Einstein and attending physician at Montefiore Medical Center.
June 17, 2015